annual cash & cash equivalents:
$2.49B-$241.80M(-8.86%)Summary
- As of today (August 23, 2025), REGN annual cash & cash equivalents is $2.49 billion, with the most recent change of -$241.80 million (-8.86%) on December 31, 2024.
- During the last 3 years, REGN annual cash & cash equivalents has fallen by -$397.40 million (-13.77%).
- REGN annual cash & cash equivalents is now -19.89% below its all-time high of $3.11 billion, reached on December 31, 2022.
Performance
REGN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$7.49B-$860.00M(-10.30%)Summary
- As of today (August 23, 2025), REGN quarterly cash & cash equivalents is $7.49 billion, with the most recent change of -$860.00 million (-10.30%) on June 30, 2025.
- Over the past year, REGN quarterly cash & cash equivalents has dropped by -$2.33 billion (-23.71%).
- REGN quarterly cash & cash equivalents is now -30.94% below its all-time high of $10.84 billion, reached on December 31, 2023.
Performance
REGN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
REGN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.9% | -23.7% |
| 3 y3 years | -13.8% | -1.0% |
| 5 y5 years | +53.8% | +138.2% |
REGN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.9% | at low | -30.9% | +6.7% |
| 5 y | 5-year | -19.9% | +53.8% | -30.9% | +147.5% |
| alltime | all time | -19.9% | >+9999.0% | -30.9% | >+9999.0% |
REGN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $7.49B(-10.3%) |
| Mar 2025 | - | $8.35B(-7.4%) |
| Dec 2024 | $2.49B(-8.9%) | $9.01B(-8.0%) |
| Sep 2024 | - | $9.80B(-0.2%) |
| Jun 2024 | - | $9.82B(-6.7%) |
| Mar 2024 | - | $10.52B(-3.0%) |
| Dec 2023 | $2.73B(-12.1%) | $10.84B(+9.4%) |
| Sep 2023 | - | $9.91B(+11.0%) |
| Jun 2023 | - | $8.93B(-0.3%) |
| Mar 2023 | - | $8.96B(+15.7%) |
| Dec 2022 | $3.11B(+7.6%) | $7.74B(+10.3%) |
| Sep 2022 | - | $7.02B(-7.2%) |
| Jun 2022 | - | $7.57B(+7.3%) |
| Mar 2022 | - | $7.05B(+23.8%) |
| Dec 2021 | $2.89B(+31.5%) | $5.69B(-1.6%) |
| Sep 2021 | - | $5.79B(+48.0%) |
| Jun 2021 | - | $3.91B(+11.6%) |
| Mar 2021 | - | $3.50B(-2.3%) |
| Dec 2020 | $2.19B(+35.6%) | $3.59B(+18.5%) |
| Sep 2020 | - | $3.03B(-3.8%) |
| Jun 2020 | - | $3.14B(-21.5%) |
| Mar 2020 | - | $4.00B(+24.5%) |
| Dec 2019 | $1.62B(+10.2%) | $3.21B(+11.7%) |
| Sep 2019 | - | $2.88B(+7.8%) |
| Jun 2019 | - | $2.67B(-17.4%) |
| Mar 2019 | - | $3.23B(+15.0%) |
| Dec 2018 | $1.47B(+80.6%) | $2.81B(+28.2%) |
| Sep 2018 | - | $2.19B(+30.2%) |
| Jun 2018 | - | $1.68B(+3.6%) |
| Mar 2018 | - | $1.62B(+15.3%) |
| Dec 2017 | $812.70M(+51.8%) | $1.41B(+2.2%) |
| Sep 2017 | - | $1.38B(+8.8%) |
| Jun 2017 | - | $1.27B(-3.0%) |
| Mar 2017 | - | $1.31B(+25.8%) |
| Dec 2016 | $535.20M(-33.9%) | $1.04B(-26.3%) |
| Sep 2016 | - | $1.41B(+34.8%) |
| Jun 2016 | - | $1.05B(+23.1%) |
| Mar 2016 | - | $849.18M(-18.8%) |
| Dec 2015 | $809.10M(+24.7%) | $1.05B(+16.7%) |
| Sep 2015 | - | $895.64M(+48.2%) |
| Jun 2015 | - | $604.25M(-18.6%) |
| Mar 2015 | - | $742.16M(-17.6%) |
| Dec 2014 | $648.72M(+21.1%) | $900.48M(-13.6%) |
| Sep 2014 | - | $1.04B(+27.6%) |
| Jun 2014 | - | $816.91M(+26.0%) |
| Mar 2014 | - | $648.13M(-6.6%) |
| Dec 2013 | $535.61M(+132.6%) | $693.98M(+55.8%) |
| Sep 2013 | - | $445.32M(-17.2%) |
| Jun 2013 | - | $537.51M(+74.7%) |
| Mar 2013 | - | $307.71M(-0.1%) |
| Dec 2012 | $230.28M(-52.4%) | $308.10M(+17.3%) |
| Sep 2012 | - | $262.55M(-12.8%) |
| Jun 2012 | - | $301.02M(-30.4%) |
| Mar 2012 | - | $432.30M(-18.0%) |
| Dec 2011 | $483.61M(+329.6%) | $526.94M(+114.6%) |
| Sep 2011 | - | $245.50M(-20.7%) |
| Jun 2011 | - | $309.68M(+36.8%) |
| Mar 2011 | - | $226.44M(-9.2%) |
| Dec 2010 | $112.57M(-45.6%) | $249.37M(-47.9%) |
| Sep 2010 | - | $479.05M(+56.4%) |
| Jun 2010 | - | $306.34M(+0.9%) |
| Mar 2010 | - | $303.64M(-11.0%) |
| Dec 2009 | $207.07M(-16.4%) | $341.33M(-10.1%) |
| Sep 2009 | - | $379.80M(-3.1%) |
| Jun 2009 | - | $391.92M(-5.8%) |
| Mar 2009 | - | $415.88M(-12.4%) |
| Dec 2008 | $247.80M | $474.75M(-28.5%) |
| Sep 2008 | - | $663.61M(-5.3%) |
| Jun 2008 | - | $700.40M(-5.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $743.25M(-3.0%) |
| Dec 2007 | $498.93M(+109.7%) | $766.46M(+93.1%) |
| Sep 2007 | - | $396.98M(-13.8%) |
| Jun 2007 | - | $460.70M(+1.8%) |
| Mar 2007 | - | $452.39M(-1.5%) |
| Dec 2006 | $237.88M(+28.9%) | $459.28M(+75.4%) |
| Sep 2006 | - | $261.89M(-4.3%) |
| Jun 2006 | - | $273.58M(-9.5%) |
| Mar 2006 | - | $302.39M(+1.3%) |
| Dec 2005 | $184.51M(+93.8%) | $298.55M(-2.9%) |
| Sep 2005 | - | $307.54M(-8.4%) |
| Jun 2005 | - | $335.81M(-5.1%) |
| Mar 2005 | - | $353.91M(+271.6%) |
| Dec 2004 | $95.23M(-19.5%) | $95.23M(-9.3%) |
| Sep 2004 | - | $105.05M(-14.5%) |
| Jun 2004 | - | $122.83M(-29.4%) |
| Mar 2004 | - | $174.03M(+47.1%) |
| Dec 2003 | $118.28M(+47.7%) | $118.28M(-60.4%) |
| Sep 2003 | - | $298.62M(+130.3%) |
| Jun 2003 | - | $129.66M(-32.3%) |
| Mar 2003 | - | $191.59M(+139.3%) |
| Dec 2002 | $80.08M(-67.6%) | $80.08M(+6.0%) |
| Sep 2002 | - | $75.57M(+8.9%) |
| Jun 2002 | - | $69.37M(-48.8%) |
| Mar 2002 | - | $135.47M(-45.2%) |
| Dec 2001 | $247.39M(+698.6%) | $247.39M(+147.5%) |
| Sep 2001 | - | $99.97M(-30.1%) |
| Jun 2001 | - | $142.96M(-22.1%) |
| Mar 2001 | - | $183.62M(+492.7%) |
| Dec 2000 | $30.98M(+30.7%) | $30.98M(-37.6%) |
| Sep 2000 | - | $49.64M(-39.3%) |
| Jun 2000 | - | $81.75M(+565.0%) |
| Mar 2000 | - | $12.29M(-48.1%) |
| Dec 1999 | $23.70M(+19.7%) | $23.70M(+0.9%) |
| Sep 1999 | - | $23.50M(+14.1%) |
| Jun 1999 | - | $20.60M(-5.5%) |
| Mar 1999 | - | $21.80M(+10.1%) |
| Dec 1998 | $19.80M(-31.5%) | $19.80M(-12.4%) |
| Sep 1998 | - | $22.60M(+0.4%) |
| Jun 1998 | - | $22.50M(+16.6%) |
| Mar 1998 | - | $19.30M(-33.2%) |
| Dec 1997 | $28.90M(-16.2%) | $28.90M(-28.3%) |
| Sep 1997 | - | $40.30M(-21.6%) |
| Jun 1997 | - | $51.40M(+84.2%) |
| Mar 1997 | - | $27.90M(-19.1%) |
| Dec 1996 | $34.50M(+5.5%) | $34.50M(-8.0%) |
| Sep 1996 | - | $37.50M(-23.3%) |
| Jun 1996 | - | $48.90M(+310.9%) |
| Mar 1996 | - | $11.90M(-63.6%) |
| Dec 1995 | $32.70M(+38.6%) | $32.70M(+454.2%) |
| Sep 1995 | - | $5.90M(-64.9%) |
| Jun 1995 | - | $16.80M(+32.3%) |
| Mar 1995 | - | $12.70M(-46.2%) |
| Dec 1994 | $23.60M(+88.8%) | $23.60M(+54.2%) |
| Sep 1994 | - | $15.30M(-15.0%) |
| Jun 1994 | - | $18.00M(+125.0%) |
| Mar 1994 | - | $8.00M(-36.0%) |
| Dec 1993 | $12.50M(-23.8%) | $12.50M(-68.5%) |
| Sep 1993 | - | $39.70M(+402.5%) |
| Jun 1993 | - | $7.90M(-21.8%) |
| Mar 1993 | - | $10.10M(-38.4%) |
| Dec 1992 | $16.40M(-37.4%) | $16.40M(-14.6%) |
| Sep 1992 | - | $19.20M(-12.7%) |
| Jun 1992 | - | $22.00M(-11.6%) |
| Mar 1992 | - | $24.90M(-5.0%) |
| Dec 1991 | $26.20M(+20.2%) | $26.20M(-25.1%) |
| Sep 1991 | - | $35.00M(-10.7%) |
| Jun 1991 | - | $39.20M(+79.8%) |
| Dec 1990 | $21.80M | $21.80M |
FAQ
- What is Regeneron Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals, Inc.?
- What is Regeneron Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Regeneron Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Regeneron Pharmaceuticals, Inc.?
- What is Regeneron Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Regeneron Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of REGN is $2.49B
What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $3.11B
What is Regeneron Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, REGN annual cash & cash equivalents has changed by -$241.80M (-8.86%)
What is Regeneron Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of REGN is $7.49B
What is the all time high quarterly cash & cash equivalents for Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $10.84B
What is Regeneron Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, REGN quarterly cash & cash equivalents has changed by -$2.33B (-23.71%)